Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Accumulated Expenses (2016 - 2025)

Marimed has reported Accumulated Expenses over the past 13 years, most recently at $9.5 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 114.41% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, up 114.41% year-over-year, with the annual reading at $9.5 million for FY2025, 114.41% up from the prior year.
  • Accumulated Expenses was $9.5 million for Q4 2025 at Marimed, up from $9.0 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $11.1 million in Q3 2021 and troughed at $1.7 million in Q1 2022.
  • The 5-year median for Accumulated Expenses is $4.6 million (2021), against an average of $5.4 million.
  • Year-over-year, Accumulated Expenses skyrocketed 256.59% in 2021 and then crashed 70.57% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $3.1 million in 2021, then fell by 1.84% to $3.1 million in 2022, then increased by 14.82% to $3.5 million in 2023, then grew by 24.96% to $4.4 million in 2024, then skyrocketed by 114.41% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Accumulated Expenses are $9.5 million (Q4 2025), $9.0 million (Q3 2025), and $7.4 million (Q2 2025).